We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Holds up Decision on Genentech's Herceptin
FDA Holds up Decision on Genentech's Herceptin
August 18, 2006
The FDA is delaying its decision on Genentech’s supplemental biologics license application (sBLA) for the breast cancer drug Herceptin for three months because of an amendment to the company’s original application.